New hope for advanced cancer: ALK-N001 enters human trials
NCT ID NCT07509684
First seen Apr 07, 2026 · Last updated May 19, 2026 · Updated 8 times
Summary
This study tests a new injectable drug, ALK-N001, in 190 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing, and to check its safety and how the body processes it. Participants will receive the drug alone, and researchers will monitor tumor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.